US › Healthcare

Celldex Therapeutics Inc (CLDX)

US · Healthcare · Biotechnology

$39.05+3.61%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$15,000
Revenue YoY
-97.8%
Net profit
$-78.7M
Profit YoY
-46.3%
EPS
$-1.18
EPS estimate
$-1.13
Net margin
-524,566.7%

EPS came in at -1.18 against a street estimate of -1.13 — a miss of 4.4%.

Key statistics

Market cap
$2.99B
Forward P/E
0.0
P/B
6.55
Book value
$6.85
EPS (TTM)
$-4.27
52-week high
$40.30
52-week low
$19.72
50-day MA
$34.11
200-day MA
$29.65
Beta
0.90

Analyst view

Analysts rate Celldex Therapeutics Inc a strong buy (14 buy, 1 hold, 0 sell out of 15) with an average price target of $57.07.

Shareholding

Insiders
0.27%
Institutions
96.19%

Largest institutional holders

FundStake
Wellington Management Company LLP10.91%
Kynam Capital Management, LP7.44%
BlackRock Inc6.84%
FMR Inc4.78%
Point72 Asset Management, L.P.4.12%
Vanguard Capital Management, LLC3.77%
State Street Corp3.57%
COMMODORE CAPITAL LP3.44%

Recent filings & reports

DocumentDate
Board / officer change · Q3 20262026-07-15
Board / officer change · Q2 20262026-06-26
Quarterly report · Q1 20262026-05-07
Results announced · Q2 20262026-05-07
Proxy statement · Q2 20262026-04-29
Material agreement · Q2 20262026-04-02
Annual report FY20252026-02-25
Quarterly report · Q3 20252025-11-10

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Celldex Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.